Drug class · Oncology & immunology
Monoclonal antibodies Drug Codes & NDCs
Products the FDA listing tags with the monoclonal-antibody chemical structure class, plus the PD-1, PD-L1 and CD20 antibody classes. Not every antibody product carries these tags, so treat this list as a starting point rather than a complete census.
FDA-listed products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-102 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-103 |
| Hyrimozadalimumab-adaz | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-107 |
| Hyrimozadalimumab-adaz | Adalimumab 20 mg/.2mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-108 |
| Hyrimozadalimumab-adaz | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-113 |
| Imfinzidurvalumab | Durvalumab 120 mg/2.4mL | Injection, SolutionIntravenous | AstraZeneca Pharmaceuticals LP | 0310-4500 |
| Imfinzidurvalumab | Durvalumab 500 mg/10mL | Injection, SolutionIntravenous | AstraZeneca Pharmaceuticals LP | 0310-4611 |
| Jemperlidostarlimab | Dostarlimab 50 mg/mL | InjectionIntravenous | GlaxoSmithKline LLC | 0173-0898 |
| Kesimptaofatumumab | Ofatumumab 20 mg/.4mL | Injection, SolutionSubcutaneous | Novartis Pharmaceuticals Corporation | 0078-1007 |
| Keytrudapembrolizumab | Pembrolizumab 25 mg/mL | Injection, SolutionIntravenous | Merck Sharp & Dohme LLC | 0006-3026 |
| Keytruda Qlexpembrolizumab and berahyaluronidase alfa-pmph | Pembrolizumab 165 mg/mL; Berahyaluronidase alfa 2000 U/mL | Injection, SolutionSubcutaneous | Merck Sharp & Dohme LLC | 0006-3083 |
| Keytruda Qlexpembrolizumab and berahyaluronidase alfa-pmph | Pembrolizumab 165 mg/mL; Berahyaluronidase alfa 2000 U/mL | Injection, SolutionSubcutaneous | Merck Sharp & Dohme LLC | 0006-5083 |
| Loqtorzitoripalimab-tpzi | Toripalimab 240 mg/6mL | InjectionIntravenous | Coherus Oncology, Inc. | 70114-340 |
| Ocrevusocrelizumab | Ocrelizumab 300 mg/10mL | InjectionIntravenous | Genentech, Inc. | 50242-150 |
| Ocrevus Zunovoocrelizumab and hyaluronidase | Ocrelizumab 920 mg/23mL; Hyaluronidase (Human recombinant) 23000 U/23mL | Injection, SolutionSubcutaneous | Genentech, Inc. | 50242-554 |
| Opdivonivolumab | Nivolumab 10 mg/mL | InjectionIntravenous | E.R. Squibb & Sons, L.L.C. | 0003-3734 |
| Opdivonivolumab | Nivolumab 10 mg/mL | InjectionIntravenous | E.R. Squibb & Sons, L.L.C. | 0003-3756 |
| Opdivonivolumab | Nivolumab 10 mg/mL | InjectionIntravenous | E.R. Squibb & Sons, L.L.C. | 0003-3772 |
| Opdivonivolumab | Nivolumab 10 mg/mL | InjectionIntravenous | E.R. Squibb & Sons, L.L.C. | 0003-3774 |
| Opdivo Qvantignivolumab and hyaluronidase-nvhy | Nivolumab 120 mg/mL; Hyaluronidase (Human recombinant) 2000 U/mL | Injection, SolutionSubcutaneous | E.R. Squibb & Sons, L.L.C. | 0003-3120 |
| Opdivo Qvantignivolumab and hyaluronidase-nvhy | Nivolumab 120 mg/mL; Hyaluronidase (Human recombinant) 2000 U/mL | Injection, SolutionSubcutaneous | E.R. Squibb & Sons, L.L.C. | 0003-6120 |
| Opdualagnivolumab and relatlimab-rmbw | Nivolumab 12 mg/mL; Relatlimab 4 mg/mL | InjectionIntravenous | E.R. Squibb & Sons, L.L.C. | 0003-7125 |
| Poteligeomogamulizumab-kpkc | Mogamulizumab 4 mg/mL | InjectionIntravenous | Kyowa Kirin, Inc. | 42747-761 |
| Praluentalirocumab | Alirocumab 75 mg/mL | Injection, SolutionSubcutaneous | Sanofi-Aventis U.S. LLC | 0024-5901 |
| Praluentalirocumab | Alirocumab 150 mg/mL | Injection, SolutionSubcutaneous | Sanofi-Aventis U.S. LLC | 0024-5902 |